Want bold action? Hire a pharma-oriented narcissist, study finds

Which pharma CEOs are most likely to make bold moves when faced with big challenges? Narcissists. If media attention runs high, narcissistic execs will attack problems aggressively by embracing disruptive technologies, a Harvard Business Review study of the industry found. Report | Abstract

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.